Overview

Update
Primary Role
Managing Partner @
Investments
27 Investments in 11 Companies
Gender:
Male
Location:
Boston
Social:

Person Details

Update

Amir Nashat is a Managing Partner in Polaris’ Boston office. Amir joined Polaris in 2002 and focuses on investments in healthcare.

Amir currently represents Polaris as a Member of the Board of Directors at AgBiome, aTyr Pharmaceuticals (NASDAQ: LIFE), BIND Therapeutics (NASDAQ: BIND), Fate Therapeutics (NASDAQ: FATE), Metacrine, Promedior Pharmaceuticals, Scholar Rock, Selecta Biosciences, and Syros Pharmaceuticals.

Additionally, Amir has served as a Member of the Board of Directors at Adnexus Therapeutics (Bristol Myers Squibb), Athenix Corporation (Bayer), Avila Therapeutics (Celgene), Living Proof, Pervasis Therapeutics (Shire Pharmaceuticals), Receptos (Celgene) and Sun Catalytix (Lockheed Martin).

At Living Proof and Sun Catalytix, Amir served as the company’s initial Chief Executive Officer.

Amir serves on the Partners Innovation Fund and is a Catalyst of the Deshpande Center for Technological Innovation at MIT.

Amir previously served on the Board of the New England Venture Capital Association.

Amir has been named to the Forbes Midas List of “Top 100 Venture Capitalists.”

Prior to joining Polaris, Amir completed his Ph.D. as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir also earned both his M.S. degree and B.S. degree in Materials Science and Mechanical Engineering at the University of California, Berkeley.

Jobs (3)

Update
Current

Managing Partner

Apr, 2002 - Current   (over 14 years)
Past
Started
Ended
Title
Company
Jan, 2008
Jan, 2011
CEO
Jan, 2005
Jan, 2011
CEO
DateInvested InRoundDetails
Jan, 2016$36M / Series B
Sep, 2015$38M / Series E
Aug, 2015$34.5M / Series B
Nov, 2014$17.5M / Series A (Lead)
Sep, 2014$20M / Series A
Jul, 2013$49M / Series D
Apr, 2013$17.5M / Series A (Lead)
Feb, 2013$30M / Series C
Mar, 2012$21.5M / Series D
May, 2011$35.99M / Series B
Oct, 2010$23M / Series C
Oct, 2010$9.5M / Series B
Jun, 2010$12.4M / Series C
Apr, 2010$15M / Series C
Sep, 2009$12M / Series C
Aug, 2009$17.38M / Series C
Feb, 2009$15.1M / Series B (Lead)
Aug, 2008$7M / Series A (Lead)
Jul, 2008$10M / Series D
Jan, 2008$9.75M / Venture
Nov, 2007$12M / Series A
Apr, 2007$10.5M / Series B (Lead)
May, 2006$14M / Series A
Jan, 2006$13M / Series C
Aug, 2005$12.4M / Series B
Jan, 2004$12.5M / Series B
Sep, 2001$8M / Series A

Education (3)

Update

Awards (1)

Images (8)

Update

Add Memberships

Add Videos